Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626236 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00626236 is a Phase 2 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 78 participants.
The verdict
NCT00626236, a Phase 2 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.
Interventions
- DRUG SPN-810
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2008-10-21 |
| Est. Completion | 2009-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626236
The ClinicalTrials.gov registry entry for NCT00626236 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPN-810 is the first listed.
NCT00626236 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626236 about?
NCT00626236 is a clinical study titled "Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems". The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.
What is the current status of trial NCT00626236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2008-10-21. Estimated completion is 2009-09-23.
What interventions are being tested in trial NCT00626236?
The interventions under investigation include: SPN-810 (DRUG).
Who is sponsoring clinical trial NCT00626236?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.